The Symptom Burden mCRPC Patients Carry Before Chemotherapy

Key Takeaways:

• In the 2025 In America survey of 206 patients with metastatic prostate cancer, 94% reported erectile dysfunction, 82% fatigue, 77% loss of libido, and 72% hot flashes. Zero percent reported no symptoms or side effects on current therapy.
• Patient open-ended questions describe androgen deprivation therapy (ADT) and novel hormonal therapy (NHT) side effects in unsparing terms; some patients say the side effects outweigh the cancer diagnosis itself.
• Reframing tolerability against the right comparator – not against zero, but against the baseline patients are already living with – supports earlier, more transparent decision-making about taxane chemotherapy when it is clinically indicated.

The tolerability conversation in metastatic castration-resistant prostate cancer (mCRPC) often rests on a comparator that does not match the patient's actual experience. The implicit framing in many consultations – "preserve quality of life by not adding chemotherapy" – assumes the patient's current baseline is a workable equilibrium.¹

The 2025 In America community survey of 206 patients with metastatic prostate cancer suggests that assumption is rarely accurate.¹

The baseline burden

The prevalence of treatment-related symptoms on current therapy in the 2025 metastatic cohort is broad and high:¹

• 94% of patients reported erectile dysfunction
• 82% reported fatigue
• 77% reported loss of libido
• 72% reported hot flashes
• 71% reported shrinkage of testicles and/or penis
• 0% reported no symptoms or side effects at all

Beyond the most prevalent symptoms, the following was reported:¹

• Weight changes – 47%
• Depression or mood changes – 46%
• Lower back, hip, or pelvic pain – 42%
• Urinary incontinence – 40%
• Cognitive impairment – 37%
• Peripheral neuropathy – 36%

The last 2 — symptoms commonly attributed to chemotherapy — are already present in a substantial minority of patients on ADT and/or NHT before any taxane exposure. Across the symptom set, the data is hard to read as a manageable equilibrium.¹

The burden extends beyond the symptom checklist. Only 6% of patients rated their current overall quality of life as Excellent; 31% rated it Fair or Poor. When asked to rate the negative impact of prostate cancer on specific aspects of their life on a 1 to 7 (No Negative Impact to Significant Negative Impact) scale, sexual health and intimacy were the most affected, with 79% rated the impact at the top of the scale (top-2 box, scores 6 or 7). Mental and emotional health (24% top-2 box) and overall quality of life (23% top-2 box) followed.

Across symptom prevalence and life-impact dimensions, the dataset describes a population often already carrying substantial cumulative burden from disease and treatment.¹

Living with ADT and NHT

What the quantitative data describes at scale, the open-ended responses in the same survey describe in voice. One patient writes that "hormone suppression is horrible and effects brain chemistry to the point it is hard to control emotions." Another puts the trade-off more starkly: "The side effects outweigh the cancer diagnosis.”¹

These are not outlier sentiments – they recur across the open-ended questions, with patients distinguishing the cancer itself from the symptom burden of the treatments that hold it in check.¹

Patients who have completed taxane chemotherapy describe a different pattern. One forum participant on the ProstateCancer.net community, after completing 5 docetaxel cycles and transitioning to radium-223 with Lupron, writes that he "feel[s] great now basically no side effects back in gym 3 days a week trying to get back the muscle I lost while I was on chemo."²

The dominant patient narrative is not that chemotherapy is unbearable. It is that the adverse event (AE) burden is substantial during treatment, recovery is real afterward, and the comparator against which chemotherapy is being judged is often the wrong one.^1,2

Reframing the comparator

The practical reframe for the clinician is to anchor the tolerability conversation in what the patient is already living with, rather than in an implicit symptom-free comparator. The NCCN Prostate Cancer guideline, the AUA Advanced Prostate Cancer guideline, and the ASCO endorsement of the Cancer Care Ontario bone-health guideline all emphasize multidisciplinary care and patient-centered communication across advanced prostate cancer treatment decisions.^3-5

In practical conversation, opening with "What are you already dealing with on your current treatment?" rather than "The side effects of chemotherapy are…" aligns the discussion with the patient's actual baseline.

The patient-voice reframe is the prerequisite to the supportive-care conversation that follows when chemotherapy is clinically indicated: recognizing that the burden side of the decision is being weighed against something other than an asymptomatic baseline, and that patients themselves typically do not hold that comparator either.